Recent Announcements
Innovative Research, Inclusive Trials, and New Funding Drives Hope for People with Parkinson’s Disease
PhotoPharmics Secures $16 Million Investment Led by Kickstart to Fund Pivotal...
Celeste® Light for PD Trial to be Presented at World Parkinson’s Congress
Celeste® Light for PD Trial to be Presented at World Parkinson’s Congress...
PhotoPharmics to Present at MTI All Stars Investor Showcase
PhotoPharmics to Present at MTI All Stars Investor Showcase DeviceTalks in...
Recruitment for Non-Invasive Parkinson’s Phase3/Pivotal Study Slated for December
Recruitment for Non-Invasive Parkinson’s Phase 3/Pivotal Study Slated for...
How Parkinson’s Affects Sleep and Vice-Versa
When most people think of Parkinson’s Disease (PD), the first symptom to come...
Care for the caregivers
“What would I do without my caregiver?” Many people with Parkinson’s disease...
“Breaking Through the FDA” (Biosphere, 2021)
“Breaking Through the FDA” (Biosphere, 2021) Innovative medical devices and...
PhotoPharmics brings renowned experts in Parkinson’s disease and other neurodegenerative diseases to advisory board
View full press release on Businesswire. PhotoPharmics brings renowned...
PhotoPharmics Appoints Dr. Karl Kieburtz as Chief Medical Officer
View full press release on Businesswire. PhotoPharmics Appoints Dr. Karl...
Utah-based PhotoPharmics Selected as Global Top 50 Startup
Utah-based PhotoPharmics Selected as Global Top 50 Startup MedTech Innovations...
Updates
Pivotal Parkinson’s Disease Clinical Trial Results Released at the International Movement Disorders Society Congress
View the full release on BusinessWirePivotal Parkinson’s Disease Clinical...
PhotoPharmics Submits FDA Application for Parkinson’s Disease Therapy
PhotoPharmics Submits FDA Application for Parkinson’s Disease Therapy 510K De...
PhotoPharmics Completes Pivotal Phototherapy Clinical Trial for Parkinson’s Disease
PhotoPharmics Completes Pivotal Phototherapy Clinical Trial for Parkinson’s...